Disease · MONDO_0005546

fibromyalgia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. fibromyalgia. Diseases, record MONDO_0005546. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005546

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: fibromyalgia; Open Targets
Open Targets ID: MONDO_0005546; Open Targets
Other names: FM, fibromyalgia syndrome; Open Targets
Disease Ontology: DOID:631; Disease Ontology
MeSH: D005356; MeSH
NCI Thesaurus: C87497; NCI Thesaurus
Orphanet: ORPHA:41842; Orphanet
Highest stage of its drugs: Approval, for 9 of its 103 drugs, from ClinicalTrials.gov, DailyMed and TTD; Open Targets

Drugs103

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PREGABALIN	CHEMBL1059	Small molecule	Approval	DailyMed	92	43	43	Drugs and targets
DULOXETINE HYDROCHLORIDE	CHEMBL1200328	Small molecule	Approval	ClinicalTrials.gov and DailyMed	34	2	2	Drugs and targets
LEVETIRACETAM	CHEMBL1286	Small molecule	Approval	TTD	2	1	1	Drugs and targets
MILNACIPRAN HYDROCHLORIDE	CHEMBL4297064	Small molecule	Approval	DailyMed	8	0	0	Drugs and targets
LEVOMILNACIPRAN HYDROCHLORIDE	CHEMBL2105732	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
IBUTAMOREN	CHEMBL13817	Small molecule	Approval	TTD	1	0	0	Drugs and targets
INDIPLON	CHEMBL262075	Small molecule	Approval	TTD	1	0	0	Drugs and targets
LEVOMILNACIPRAN	CHEMBL99946	Small molecule	Approval	TTD	1	0	0	Drugs and targets
TROPISETRON	CHEMBL56564	Small molecule	Approval	TTD	1	0	0	Drugs and targets
DULOXETINE	CHEMBL1175	Small molecule	Phase 3	ClinicalTrials.gov	20	20	20	Drugs and targets

1 to 10 of 103

See all 103 drugs

Targets147

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SLC6A2	Sodium-dependent noradrenaline transporter	17	Norepinephrine transporter inhibitor; Sodium-dependent noradrenaline transporter releasing agent	Approval	https://conductscience.org/library/genes/6530	Drugs and targets
SLC6A4	Sodium-dependent serotonin transporter	17	Serotonin transporter inhibitor; Sodium-dependent serotonin transporter releasing agent	Approval	https://conductscience.org/library/genes/6532	Drugs and targets
ADRA2A	Adrenergic receptor	4	Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist; Adrenergic receptor alpha-2 antagonist	Phase 2	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor	4	Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist; Adrenergic receptor alpha-2 antagonist	Phase 2	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor	4	Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist; Adrenergic receptor alpha-2 antagonist	Phase 2	https://conductscience.org/library/genes/152	Drugs and targets
GRIN2A	Glutamate [NMDA] receptor	4	Glutamate [NMDA] receptor negative allosteric modulator; Glutamate [NMDA] receptor subunit epsilon 1 antagonist	Phase 3	https://conductscience.org/library/genes/2903	Drugs and targets
HTR2A	5-hydroxytryptamine receptor 2A	4	Serotonin 2a (5-HT2a) receptor agonist; Serotonin 2a (5-HT2a) receptor antagonist	Phase 3	https://conductscience.org/library/genes/3356	Drugs and targets
HTR2C	5-hydroxytryptamine receptor 2C	4	Serotonin 2c (5-HT2c) receptor antagonist	Phase 3	https://conductscience.org/library/genes/3358	Drugs and targets
ADRB1	Adrenergic receptor	3	Adrenergic receptor agonist; Beta-1 adrenergic receptor antagonist	Phase 2	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Adrenergic receptor	3	Adrenergic receptor agonist; Beta-2 adrenergic receptor antagonist	Phase 2	https://conductscience.org/library/genes/154	Drugs and targets

1 to 10 of 147

See all 147 targets

Trials180

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 5 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02234583	An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia	Phase 3	2,485	2020-07-23	Pain Associated With Fibromyalgia	MIROGABALIN	Its record names the disease	ClinicalTrials.gov
NCT02187471	Treatment of Pain Associated With Fibromyalgia	Phase 3	1,301	2020-11-09	Pain Associated With Fibromyalgia	MIROGABALIN, PREGABALIN	Its record names the disease	ClinicalTrials.gov
NCT02146430	Treatment of Pain Associated With Fibromyalgia	Phase 3	1,293	2020-11-09	Pain Associated With Fibromyalgia	MIROGABALIN	Its record names the disease	ClinicalTrials.gov
NCT02187159	Treatment of Pain Associated With Fibromyalgia	Phase 3	1,270	2020-11-09	Pain Associated With Fibromyalgia	MIROGABALIN, PREGABALIN	Its record names the disease	ClinicalTrials.gov
NCT00314249	Study of Milnacipran for the Treatment of Fibromyalgia	Phase 3	1,025	2009-11-02	Fibromyalgia	MILNACIPRAN	Its record names the disease	ClinicalTrials.gov
NCT00333866	Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin In Patients With Fibromyalgia.	Phase 3	747	2009-05-13	Fibromyalgia	PREGABALIN	Its record names the disease	ClinicalTrials.gov
NCT00423813	A Safety and Efficacy Study of Xyrem® (Sodium Oxybate) to Treat Fibromyalgia.	Phase 3	573	2012-01-10	Fibromyalgia	SODIUM OXYBATE	Its record names the disease	ClinicalTrials.gov
NCT00423605	Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyalgia.	Phase 3	560	2011-10-20	Fibromyalgia	SODIUM OXYBATE	Its record names the disease	ClinicalTrials.gov
NCT00371137	A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia	Phase 3	548	2011-11-30	Fibromyalgia	SODIUM OXYBATE	Its record names the disease	ClinicalTrials.gov
NCT01773993	Special Investigation of Pregabalin for Fibromyalgia (Regulatory Post Marketing Commitment Plan)		534	2019-05-03	Pain Associated With Fibromyalgia	PREGABALIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 180

See all 180 trials

Comparisons in its trials50

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
DS-5565 15 mg QD Modal vs DS-5565 15 mg BID Modal: deaths from any cause	3 of 847	2 of 1,241	2,088	NCT02234583	Trial comparisons
DS-5565 15 mg QD Modal vs DS-5565 15 mg BID Modal: serious adverse events	41 of 847	94 of 1,241	2,088	NCT02234583	Trial comparisons
Milnacipran vs Placebo: serious adverse events	10 of 516	7 of 509	1,025	NCT00314249	Trial comparisons
TNX-102 SL Tablet, 2.8 mg vs Placebo SL Tablet: Proportion of Patients With ≥30% Pain Improvement	75 of 262	58 of 257	519	NCT02436096	Trial comparisons
TNX-102 SL Tablet, 2.8 mg vs Placebo SL Tablet: Patient's Global Impression of Change (PGIC)	62 of 262	42 of 257	519	NCT02436096	Trial comparisons
TNX-102 SL Tablet, 2.8 mg vs Placebo SL Tablet: deaths from any cause	0 of 262	0 of 256	518	NCT02436096	Trial comparisons
TNX-102 SL Tablet, 2.8 mg vs Placebo SL Tablet: serious adverse events	3 of 262	4 of 256	518	NCT02436096	Trial comparisons
TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet: deaths from any cause	0 of 256	0 of 258	514	NCT04508621	Trial comparisons
TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet: Number of Patients With a Patient's Global Impression of Change (PGIC) Rating of Very Much Improved or Much Improved	76 of 256	56 of 258	514	NCT04508621	Trial comparisons
TNX-102 SL Tablet, 5.6 mg vs Placebo SL Tablet: serious adverse events	6 of 256	0 of 258	514	NCT04508621	Trial comparisons

1 to 10 of 50

See all 50 comparisons in its trials

Papers from its trials98

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41595724	RESULT	1	PubMed
38336340	RESULT	1	PubMed
37689323	RESULT	1	PubMed
36352022	RESULT	1	PubMed
34785366	RESULT	1	PubMed
32710772	RESULT	1	PubMed
31356985	RESULT	1	PubMed
31082018	RESULT	1	PubMed
30127596	RESULT	1	PubMed
28408193	RESULT	1	PubMed

1 to 10 of 98

See all 98 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005546

GET https://conductscience.org/api/diseases/v1/MONDO_0005546/drugs?page=2

API reference For AI assistants